GDR

Genedrive PLC

Health Care First-pass screen £15m

290/1000 Overall fit

AI beneficiary 35% 25

Operating leverage 25% 35

Valuation 25% 30

Downside protection 15% 25

First-pass take

Genedrive is a precision-medicine diagnostics firm with two NICE-recommended, CE-IVD-approved pharmacogenetic tests in early NHS rollout (MT-RNR1 at 14 sites; CYP2C19 in pilot). Revenue doubled to £1m in FY25, but company remains loss-making (£5.2m operating loss), pre-commercial, and critically under-capitalized: £0.32m cash as of Nov 25 against £0.35m monthly burn. Material going-concern warning; no AI exposure.

Flags

loss-makinggoing-concernmicro-capno-ai-exposurecustomer-concentrationcash-constrainedpre-commercialregulatory-dependentno-valuation-data